Trials of Bharat Biotech’s Covaxin suspended in Brazil


Posted on 24 July 2021


For Illustration Purpose Only.


The clinical trials of Bharat Biotech's COVID-19 vaccine, Covaxin, in Brazil have been halted following the termination of the company's agreement with its partner there, according to the South American country's health regulator. Bharat Biotech cancelled the MoU it signed with Precisa Medicamentos and Envixia Pharmaceuticals LL.C for their COVID-19 vaccine Covaxin for the Brazilian market on Friday, July 23, 2021. The agreement was terminated when a deal with the Brazilian government for the provision of 20 million doses of the vaccine sparked controversy and prompted an investigation by Brazilian authorities. Bharat Biotech's Brazilian partner, Precisa Medicamentos, assisted with regulatory applications, licensure, distribution, insurance, and the conduct of phase III clinical studies, among other things. The Brazilian government has temporarily suspended Covaxin's order as a result of the graft allegations.



Key Points


  • The clinical trials of Bharat Biotech's COVID-19 vaccine, Covaxin, in Brazil have been halted following the termination of the company's agreement with its partner there, according to the South American country's health regulator. 

  • The agreement was terminated when a deal with the Brazilian government for the provision of 20 million doses of the vaccine sparked controversy and prompted an investigation by Brazilian authorities.


Follow Us On Google Newsstand: Click Here